TGBA01AD

TGBA01AD
Clinical data
Other names	FKB01MD
Routes of; administration	By mouth
Pharmacokinetic data
Bioavailability	17%
Elimination half-life	4 hours

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT_1A and 5-HT_1D receptor agonist, and 5-HT₂ receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.^[2]^[1]^[3] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.^[4]

References

^ ^a ^b ^c "FKB01MD". Fabre-Kramer.
^ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. S2CID 16286323.
^ Żmudzka E, Sałaciak K, Sapa J, Pytka K (October 2018). "Serotonin receptors in depression and anxiety: Insights from animal studies". Life Sciences. 210: 106–124. doi:10.1016/j.lfs.2018.08.050. PMID 30144453. S2CID 52090587.
^ "TGBA01AD". AdisInsight. Springer Nature Switzerland AG.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[FabreKramer2015-1] "FKB01MD". Fabre-Kramer.

[PharmaMed2013-2] "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. S2CID 16286323.

[pmid30144453-3] Żmudzka E, Sałaciak K, Sapa J, Pytka K (October 2018). "Serotonin receptors in depression and anxiety: Insights from animal studies". Life Sciences. 210: 106–124. doi:10.1016/j.lfs.2018.08.050. PMID 30144453. S2CID 52090587.

[AdisInsight-4] "TGBA01AD". AdisInsight. Springer Nature Switzerland AG.

[1]

[2]

[3]

[4]

See also

References